Merck & Co earnings were $8.9B for the trailing 12 months ending Mar 31, 2026, with -48.2% growth year over year. The latest MRK earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$4.2B, down 243.1% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, MRK reported annual earnings of $18.3B, with 6.6% growth.
MRK past earnings growth
How has MRK's earnings growth performed historically?
On MRK's earnings call on Invalid Date, Merck & Co (NYSE: MRK) reported Q1 2026 earnings per share (EPS) of -$1.72, up 185.57% year over year. Total MRK earnings for the quarter were -$4.24 billion. In the same quarter last year, Merck & Co's earnings per share (EPS) was $2.01.
As of the last Merck & Co earnings report, Merck & Co is currently profitable. Merck & Co's net profit (also called net income) for the twelve months ending Mar 31, 2026 was $8.94 billion, a 48.75% decrease year over year.
What was MRK's earnings growth in the past year?
As of Merck & Co's earnings date in Invalid Date, Merck & Co's earnings has grown -48.19% year over year. This is 89.39 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 41.2%. MRK earnings in the past year totalled $8.94 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.